Havemann K, Egbring R, Gropp C, Schmidt M, Sodomann C P
Klin Wochenschr. 1977 Aug 15;55(16):801-9. doi: 10.1007/BF01651269.
A decrease in fibrin stabilizing factor (Factor XIII) is the most frequent coagulation disorder seen in adults with acute leukemia. Patients with prominent reduction of factor XIII (FSF) (less than 50%) were substituted with a factor XIII concentrate from human placenta, and factor XIII plasma concentration and bleeding tendency were followed up during the course of the disease. After substitution plasma, factor XIII activity went up to normal levels in most of the patients. As compared to the course of 12 patients with distinct factor XIII reduction without factor XIII therapy, there were less bleeding complications in 13 courses of patients with prominent reduction of factor XIII substituted with factor XIII concentrate and in 11 with normal or only slightly reduced factor XIII levels.
纤维蛋白稳定因子（因子 XIII）降低是成人急性白血病中最常见的凝血障碍。因子 XIII（FSF）显著降低（低于 50%）的患者用人胎盘来源的因子 XIII 浓缩物替代治疗，并在疾病过程中随访因子 XIII 血浆浓度和出血倾向。替代治疗后，大多数患者的因子 XIII 活性恢复到正常水平。与 12 例未接受因子 XIII 治疗且因子 XIII 明显降低的患者病程相比，13 例接受因子 XIII 浓缩物替代治疗且因子 XIII 显著降低的患者病程以及 11 例因子 XIII 水平正常或仅轻度降低的患者病程中，出血并发症较少。
